TY - JOUR T1 - Diffusion basis spectrum imaging in post-hemorrhagic hydrocephalus of prematurity JF - medRxiv DO - 10.1101/2021.01.12.21249706 SP - 2021.01.12.21249706 AU - Albert M. Isaacs AU - Jeffrey J. Neil AU - James P. McAllister AU - Sonika Dahiya AU - Leandro Castaneyra-Ruiz AU - Harri Merisaari AU - Haley E. Botteron AU - Dimitrios Alexopoulous AU - Ajit George AU - Sun Peng AU - Diego Morales AU - Yan Yan AU - Sheng-Kwei Song AU - David D. Limbrick, Jnr. AU - Christopher D. Smyser Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/01/13/2021.01.12.21249706.abstract N2 - Objective The debilitating neurological deficits of neonatal post-hemorrhagic hydrocephalus (PHH) have been linked to periventricular white matter injury. To improve understanding of the deleterious mechanisms underlying PHH-related brain injury, this study applied diffusion basis spectrum imaging (DBSI) for the first time in neonates, modeling white matter fibers to assess axonal and myelin integrity, fiber density, and extra-fiber pathologies including cellularity, edema, and inflammation. The objectives of the study were to characterize DBSI measures in key periventricular white matter tracts of PHH infants, associate those diffusion measures with ventricular size, and utilize postmortem white matter histology to compare with the MRI findings.Method A prospective cohort of very preterm infants (n=95) underwent MRI at term equivalent age, of which 68 were controls (VPT group), 15 had high-grade intraventricular hemorrhage without hydrocephalus (IVH group), and 12 had PHH (PHH group). DBSI metrics extracted from manually segmented corpus callosum (CC), corticospinal tracts (CST), and optic radiations (OPRA) included fiber level axial diffusivity (FAD), fiber radial diffusivity (FRD), fiber fractional anisotropy (FFA), fiber fraction (FF), restricted fractions (RF), and non-restricted fractions (NRF). All measures were contrasted across groups and correlated with frontal occipital horn ratio (FOHR), a measure of ventricular size. Postmortem immunohistochemistry was performed on the CC of 10 preterm infants (five VPT, three IVH, and two PHH) and two full-term infants who died from non-neurologic causes assessing white matter intra- and extra-fiber pathologies, as well as the integrity of the adjoining ventricular and subventricular zones.Results Except for FF in the CC, there were no differences in all measures between IVH and VPT infants. In the unmyelinated CC, PHH had the lowest FF, FAD, and FFA and the highest RF. In the CC, FOHR related negatively with FAD, FFA, and FF and positively with RF. In the myelinated CST, PHH had the lowest FAD, FFA, and FF and the highest FRD and RF. FOHR related negatively to FAD and FFA and positively with NRF and FRD. In the OPRA, PHH was associated with the lowest FF and the highest RF, NRF, and FAD. FOHR related positively with FAD and NRF and negatively with FF. On postmortem tissues, PHH was associated with the highest white matter cellularity counts, variable amounts of cytoplasmic vacuolation, and the lowest synaptophysin marker intensity. The adjoining ventricular and subventricular zones in PHH had poor cytoarchitecture on H&E staining and relatively increased expression of GFAP and IBA1.Conclusions This initial utilization of DBSI to investigate neonatal brain development and injury demonstrated that PHH was associated with diffuse periventricular white matter injury, with tract-specific microstructural patterns and severity of axonal injury, myelin injury, white matter fiber loss, hypercellularity, and inflammation. While axonal injury was present in the CST and unmyelinated CC, myelin injury occurred only in the CST. The OPRA predominantly showed inflammation with myelin preservation. White matter cellular infiltration occurred in all tracts. Postmortem immunohistochemistry confirmed the imaging findings of decreased axonal fiber density, sparser fiber architecture, and increased cellular infiltration. Larger ventricular size was associated with greater white matter disruption. Building upon these results, DBSI provides an innovative approach for investigating the complex neuropathological effects of PHH on periventricular white matter microstructure.Competing Interest StatementDrs. Limbrick and McAllister have received research funds and/or research equipment for unrelated projects from Medtronic, Inc. and Microbot Medical, Inc. The authors have no personal, financial, or institutional interest in any of the materials, or devices described in this article.Funding StatementThis work was supported by the Vanier Canada Graduate Scholarship [grant number 396212]; National Institutes of Health [grant numbers K02 NS089852, K23 NS075151, K23 MH105179, TL1 TR002344, P30 NS098577, R01 MH113570, R01 HD061619, R01 HD057098, R01 NS047592 and U01 EY025500]; Child Neurology Foundation; Cerebral Palsy International Research Foundation; The Dana Foundation; March of Dimes Prematurity Research Center at Washington University; The Doris Duke Charitable Foundation; Orion Pharma Research Foundation; and the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health [grant number U54 HD087011]. None of the organizations listed had any role in the study design, data collection, data analysis, data interpretation, writing or decision to submit the report for publication. Our funding sources had no involvement in study design, data analysis, writing the report, or the decision to submit the article for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Washington University Human Research Protection OfficeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data supporting the results of this study are included in the manuscript ER -